Vinpocetine for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Vinpocetine for Health & Longevity

Created on 09/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A modified plant compound that widens brain blood vessels and damps inflammation. The strongest human signal is less lasting disability when it is added in the first days after a stroke, though deaths are unchanged. Memory claims are split, and ordinary doses may be too low. Animal pregnancy loss and unreliable product content are the serious concerns. (Full Review)

Protocol

Standard oral regimen
5–10 mg three times daily
With meals, totalling 15–30 mg/day, as used in the dementia and chronic-ischemia trials.
Split dosing rather than a single dose
Two or three divided doses
The short half-life means once-daily dosing leaves most of the day unexposed.
Best time of day
Breakfast, midday, late-afternoon meals
A dose after the early evening is the pattern associated with reported insomnia.
Time to effect
Cognitive and functional change
12–16 weeks
The interval at which trials measured it.
Perfusion and rheological changes
Single infusion to first days
Blood flow and blood viscosity shift before any clinical change.
Hearing
6 months
The hearing study saw nothing before six months.

Benefits

Contraindications
  • Pregnancy, attempted conception, or sexual activity without reliable contraception in women of childbearing potential
  • Breastfeeding
  • Bleeding disorders, or platelet count below 50 × 109/L
  • Current warfarin or other vitamin K antagonist therapy
  • Severe hepatic impairment (Child-Pugh Class C)
  • Symptomatic hypotension, or resting systolic blood pressure below 100 mmHg
  • Recent intracranial haemorrhage (<90 days) or known untreated cerebral aneurysm
  • Active demyelinating disease (as in multiple sclerosis) in a remission phase
    •
Key Interactions
  • Anticoagulants (apixaban, rivaroxaban, dabigatran)
  • Antiplatelet drugs (aspirin, clopidogrel, ticagrelor)
  • P-glycoprotein substrates (digoxin, dabigatran, colchicine)
  • CYP2C9 substrates (glimepiride, celecoxib, phenytoin)
  • Antihypertensives (amlodipine, lisinopril, losartan)
  • Antiseizure medications (carbamazepine, valproate, levetiracetam)
  • QT-prolonging medicines (amiodarone, sotalol, citalopram)
  • Over-the-counter analgesics (ibuprofen, naproxen, high-dose aspirin)
  • Antiplatelet supplements (fish oil, Ginkgo biloba, garlic extract)
  • Blood-pressure-lowering supplements (beetroot or dietary nitrate, magnesium, taurine)
  • Other interventions (thrombolysis, mechanical thrombectomy, cerebral angiography)
  • No interaction with proton pump inhibitors (omeprazole, esomeprazole)
    •

Risk & Side Effects

  • High: Transient vasodilatory and gastrointestinal adverse effects
    •
  • Medium: Absent or wildly variable active ingredient in commercial supplements
  • Low: Sleep disturbance and daytime drowsiness; increased bleeding tendency alongside antiplatelet or anticoagulant therapy; transient hypotension at high or intravenous doses; irregular heartbeat at prescription doses
  • Speculative: Embryo-fetal harm and pregnancy loss; agranulocytosis; impaired repair of the myelin sheath

Monitoring

Marker Target Why
Blood pressure, seated and standing 110–125 / 70–80 mmHg, <10 mmHg systolic drop on standing Detects vasodilatory hypotension and dizziness during titration
Full blood count with differential (absolute neutrophil count) Neutrophils 2.0–6.0 × 109/L Screens for the rare agranulocytosis signal and for bleeding-relevant platelet fall
Platelet count 200–400 × 109/L Quantifies the reserve against the additive antiplatelet effect
Alanine aminotransferase (a liver enzyme) <25 U/L in men, <20 U/L in women Hepatic hydrolysis is the sole clearance route, so liver strain alters exposure
Creatinine with estimated glomerular filtration rate Filtration rate >90 mL/min/1.73 m² Baseline for the animal-only renal claims and for co-prescribed drug clearance
Fibrinogen 200–300 mg/dL Identifies the raised-viscosity state in which rheological benefit has been shown
High-sensitivity C-reactive protein <1.0 mg/L Tracks the inflammation-suppressing action that trials measured indirectly
Montreal Cognitive Assessment (a 30-point cognitive screen) ≥26 of 30, or no decline from the individual's own baseline Converts a vague sense of sharper thinking into a repeatable number
Serum or urine human chorionic gonadotropin (the pregnancy hormone) Negative The one serious documented harm is reproductive, making this the gating test

Cadence: Blood pressure at week 1 and week 2 during titration, then every 3–6 months; full blood count, liver enzymes and the cognitive score at 3 months, then every 6–12 months; inflammatory and clotting markers only if they were abnormal at baseline; pregnancy test before the first dose and whenever pregnancy is possible.

Qualitative Assessment

  • Word-finding and name recall in conversation, noted weekly rather than recalled at the next visit
  • Mental stamina late in the working day, and how long focused work can be sustained
  • Frequency and intensity of headache, facial flushing and lightheadedness, with the time since the last dose
  • Sleep onset latency and night waking, since both directions have been reported
  • Tinnitus loudness and clarity of speech in noisy rooms, for those using it with hearing complaints
  • Unexplained bruising, gum bleeding or prolonged bleeding from small cuts
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.